What is the treatment for corneal ulcer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Corneal ulcers should be treated promptly with topical antibiotic eye drops, typically fluoroquinolones like ciprofloxacin 0.3%, ofloxacin 0.3%, or levofloxacin 1.5%, applied every 1-2 hours initially. The choice of antibiotic should be guided by the severity of the ulcer and the suspected causative organism, with fortified antibiotics considered for large and/or visually significant corneal infiltrates 1.

Key Considerations

  • For central or severe keratitis, a loading dose such as every 5 to 15 minutes followed by frequent applications, such as every hour, is recommended 1.
  • Cycloplegic agents may be used to decrease synechiae formation and decrease pain from anterior segment inflammation associated with bacterial keratitis 1.
  • Single-drug therapy using a fluoroquinolone has been shown to be as effective as combination therapy utilizing antibiotics that are fortified by increasing their concentration over commercially available topical antibiotics 1.

Management and Follow-up

  • Treatment should begin immediately after corneal scraping for culture, with drops gradually tapered as the ulcer improves, usually continuing for 7-10 days 1.
  • Pain management with oral analgesics and cycloplegic drops like cyclopentolate 1% helps reduce discomfort and prevent complications.
  • Antifungal medications (natamycin 5% or amphotericin B) are necessary for fungal ulcers, while acanthamoeba ulcers require polyhexamethylene biguanide or chlorhexidine.
  • Patients should avoid contact lens wear during treatment and follow strict hygiene practices, with severe ulcers potentially requiring hospitalization 1.
  • Follow-up within 24-48 hours is essential to assess treatment response and adjust therapy if needed, taking into account the potential for increased resistance to fluoroquinolones in certain pathogens 1.

From the FDA Drug Label

PRECAUTIONS: General. FOR TOPICAL OPHTHALMIC USE ONLY — NOT FOR INJECTION. Failure of improvement of keratitis following 7-10 days of administration of the drug suggests that the infection may be caused by a microorganism not susceptible to natamycin. The treatment for corneal ulcer (keratitis) may include natamycin if the microorganism is susceptible to it. The treatment should be re-evaluated after 7-10 days if there is no improvement, and additional laboratory studies may be necessary 2.

From the Research

Treatment Options for Corneal Ulcers

  • Infectious ulcers usually resolve with antimicrobial treatment 3, 4
  • Noninfectious ulcers can often be resolved by eliminating toxic medications and providing surface support with lubrication and collagenase inhibitors 3
  • Resistant ulcers may need more aggressive therapy with bandage contact lenses, tarsorrhaphy, or autologous serum 3
  • Ulcers impending perforation require urgent surgical management, such as tissue glue, conjunctival flaps, or keratoplasty 3, 5
  • Topical steroids are useful when the ulceration is secondary to inflammatory mediators, but they are contraindicated in corneal melts with minimal inflammation 3
  • Systemic immunomodulation is required in addition to topical therapy in the presence of autoimmune disease 3

Pharmacological Treatment

  • Topical application with a broad-spectrum antimicrobial remains the preferred method for the pharmacological management of infectious corneal ulcers 4
  • Gatifloxacin 0.3% ophthalmic solution has been shown to be effective in the treatment of acute bacterial keratitis 6
  • Corneal cross-linking (CXL) has been used as an adjunct or stand-alone treatment for corneal ulcers, with approximately 200 clinical cases reported in the literature 7

Surgical Management

  • Surgical strategies are available for the treatment of corneal ulceration and perforation, including tissue glue, conjunctival flaps, and keratoplasty 5
  • The option depends on the etiology and parameters of the ulceration, such as size, depth, and location 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacological treatment for infectious corneal ulcers.

Expert opinion on pharmacotherapy, 2013

Research

Update on surgical management of corneal ulceration and perforation.

Romanian journal of ophthalmology, 2019

Research

Efficacy of Gatifloxacin in Acute Bacterial Corneal ulcer.

Pakistan journal of medical sciences, 2013

Research

Corneal cross-linking in the treatment of corneal ulcers.

Current opinion in ophthalmology, 2016

Related Questions

What is the treatment of choice for corneal ulceration?
What is the recommended management for corneal ulcers?
Can a corneal ulcer lead to endophthalmitis?
What is the treatment for a 6mm corneal ulceration with no foreign body?
What is the treatment for a corneal ulcer?
What is the most likely diagnosis of a 3mm nodule located in the fat anterior to the psoas muscle below the lower pole of the left kidney in a patient with a history of partial nephrectomy (surgical removal of a portion of the kidney) for a 1.3 cm chromophobe renal cell carcinoma (RCC)?
What is the most likely diagnosis of a 3mm nodule located in the fat anterior to the psoas muscle below the lower pole of the left kidney in a patient with a history of partial nephrectomy (surgical removal of a portion of the kidney) for a 1.3 cm chromophobe renal cell carcinoma (RCC)?
What is the most likely diagnosis of a 3mm nodule located in the fat anterior to the psoas muscle below the lower pole of the left kidney in a patient with a history of partial nephrectomy (surgical removal of a portion of the kidney) for a 1.3 cm chromophobe renal cell carcinoma (RCC)?
What is the most likely diagnosis of a 3mm solid nodule located in the fat anterior to the psoas muscle below the lower pole of the left kidney in a patient with a history of partial nephrectomy (surgical removal of a portion of the kidney) for a 1.3 cm chromophobe renal cell carcinoma (RCC)?
What is the most likely diagnosis of a 3mm solid nodule located in the fat anterior to the psoas muscle below the lower pole of the left kidney in a patient with a history of partial nephrectomy (surgical removal of a portion of the kidney) for a 1.3 cm chromophobe renal cell carcinoma (RCC)?
What is the most likely diagnosis of a 3mm solid nodule located in the fat anterior to the psoas muscle below the lower pole of the left kidney in a patient with a history of partial nephrectomy (surgical removal of a portion of the kidney) for a 1.3 cm chromophobe renal cell carcinoma (RCC)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.